Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30431325 | 1.00 | CYP19A1 (0.47) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL9770755 | 0.81 | CYP3A4 (0.43) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL24608491 | 0.81 | CYP19A1 (0.50) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL30589181 | 0.81 | CYP19A1 (0.50) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL4196221 | 0.78 | CYP19A1 (0.55) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL29676826 | 0.78 | CYP19A1 (0.55) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL3235238 | 0.78 | CYP19A1 (0.55) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL7614593 | 0.78 | CYP3A4 (0.48) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL30911310 | 0.76 | KCNA5 (0.47) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 | |
| SCHEMBL27404978 | 0.76 | KCNA5 (0.47) | CYP19A1CYP3A4LMNACYP1A2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062710-A1 | Method For Producing 3-(Pyridyl-2-Amino)Propionitrile And Analogues Thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2020-02-27 | — | — | US | disclosed |
| EP-3553051-A1 | METHOD FOR PRODUCING 3-(PYRIDYL-2-AMINO)PROPIONITRILE AND ANALOGUES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2019-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062710-A1 | Method For Producing 3-(Pyridyl-2-Amino)Propionitrile And Analogues Thereof | PDXK, PAH, PNPO | CYP19A1 222/4885CYP3A4 31/4885LMNA 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.